115 related articles for article (PubMed ID: 4066222)
21. C-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis.
Davidoff AN; Mendelow BV
Anticancer Res; 1993; 13(4):1167-70. PubMed ID: 8352540
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.
Davila E; Klein L; Vogel CL; Johnson R; Ostroy F; Browning S; Gorowski E; Furner RL; Presant CA
J Clin Oncol; 1985 Jan; 3(1):121-7. PubMed ID: 3965629
[TBL] [Abstract][Full Text] [Related]
23. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
[TBL] [Abstract][Full Text] [Related]
24. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Invest New Drugs; 1984; 2(2):191-9. PubMed ID: 6469514
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.
Eder JP; Elias AD; Ayash L; Wheeler CA; Shea TC; Schnipper LE; Frei E; Antman KH
Cancer Chemother Pharmacol; 1991; 29(1):61-5. PubMed ID: 1742850
[TBL] [Abstract][Full Text] [Related]
27. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557).
Kohn FR; Landkamer GJ; Sladek NE
Immunopharmacol Immunotoxicol; 1987; 9(2-3):163-76. PubMed ID: 3437102
[TBL] [Abstract][Full Text] [Related]
28. High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines.
Fritz G; Hengstler JG; Kaina B
Cancer Res; 1997 Feb; 57(3):454-60. PubMed ID: 9012473
[TBL] [Abstract][Full Text] [Related]
29. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
Rizzoli V; Mangoni L
Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
32. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
Bremner DN; McCormick JS; Thomson JW
Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
[No Abstract] [Full Text] [Related]
33. Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.
Zeller WJ; Berger MR; Matys R; Schuhmacher J
Invest New Drugs; 1984; 2(2):175-80. PubMed ID: 6469512
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.
Uckun FM; Chandan-Langlie M; Dockham PA; Aeppli D; Sladek NE
Leuk Lymphoma; 1994 May; 13(5-6):417-28. PubMed ID: 8069187
[TBL] [Abstract][Full Text] [Related]
35. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
37. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
Sreerama L; Sladek NE
Cancer Res; 1994 Apr; 54(8):2176-85. PubMed ID: 8174125
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of cyclophosphamide (NSC 26271) by 72-hour continuous intravenous infusion.
Bedikian AY; Bodey GP
Am J Clin Oncol; 1983 Jun; 6(3):365-8. PubMed ID: 6846253
[TBL] [Abstract][Full Text] [Related]
39. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide.
Olivieri A; Poloni A; Montanari M; Cantori I; Corvatta L; Masia MC; Curzi L; Mancini S; Leoni P
J Hematother; 1997 Apr; 6(2):137-44. PubMed ID: 9131443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
